HPV prevalence and genotype distribution among women in sanming, China: a retrospective analysis before large-scale vaccination.

IF 3.1 2区医学 Q3 IMMUNOLOGY

Infectious Agents and Cancer Pub Date : 2025-07-09 DOI:10.1186/s13027-025-00678-8

Xiang Jiang, Jia Luo, Dexiang Zhuo, Chunjing Chen, Yaru Li, Shiying Chen, Yingming Sun, Huanming Lin

{"title":"HPV prevalence and genotype distribution among women in sanming, China: a retrospective analysis before large-scale vaccination.","authors":"Xiang Jiang, Jia Luo, Dexiang Zhuo, Chunjing Chen, Yaru Li, Shiying Chen, Yingming Sun, Huanming Lin","doi":"10.1186/s13027-025-00678-8","DOIUrl":null,"url":null,"abstract":"Background: To study the prevalence of HPV in Sanming, China before conducting large-scale HPV vaccination is important to guide public health preventive measures and maximize the effectiveness of vaccination.Objective: Provide an overall understanding of the prevalence of HPV in Sanming to help guide HPV screening and vaccine selection in the future.Methods: A retrospective analysis of 11,886 female patients who underwent cervical screening was performed. We analyzed the overall HPV prevalence in the region, the prevalence based on each age group and different genotypes and the distribution of HPV with different pathological diagnoses.Results: The overall HPV prevalence was 17.85%, with peak positivity in the ≤ 20-year group (42.24%) and secondary elevation in 61-70-year-olds (31.90%). HPV52 (23.37%), HPV58 (14.00%), and HPV16 (11.40%) constituted the dominant genotypes. Among 2,122 HPV-positive patients, pathological diagnoses included: chronic cervicitis (83.22%, 1,766/2,122; predominantly HPV52 [22.88%]), low-grade squamous intraepithelial lesions (LSIL, 11.50%, 244/2,122; HPV52 [29.92%]), high-grade SIL (HSIL, 3.49%, 74/2,122; HPV16 [40.54%]), and cervical cancer (1.79%, 38/2,122; HPV16 [52.63%]). Notably, HPV16 prevalence increased significantly with lesion severity.Conclusion: This study found that the overall HPV infection rate in Sanming, China, was slightly higher than in other regions of the country, and the main prevalent genotypes were HPV52 and HPV58. In order to maximize patient benefit, vaccine selection should ideally cover other common genotypes in the region, in addition to HPV16 and HPV18.","PeriodicalId":13568,"journal":{"name":"Infectious Agents and Cancer","volume":"20 1","pages":"45"},"PeriodicalIF":3.1000,"publicationDate":"2025-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12243287/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Infectious Agents and Cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s13027-025-00678-8","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: To study the prevalence of HPV in Sanming, China before conducting large-scale HPV vaccination is important to guide public health preventive measures and maximize the effectiveness of vaccination.

Objective: Provide an overall understanding of the prevalence of HPV in Sanming to help guide HPV screening and vaccine selection in the future.

Methods: A retrospective analysis of 11,886 female patients who underwent cervical screening was performed. We analyzed the overall HPV prevalence in the region, the prevalence based on each age group and different genotypes and the distribution of HPV with different pathological diagnoses.

Results: The overall HPV prevalence was 17.85%, with peak positivity in the ≤ 20-year group (42.24%) and secondary elevation in 61-70-year-olds (31.90%). HPV52 (23.37%), HPV58 (14.00%), and HPV16 (11.40%) constituted the dominant genotypes. Among 2,122 HPV-positive patients, pathological diagnoses included: chronic cervicitis (83.22%, 1,766/2,122; predominantly HPV52 [22.88%]), low-grade squamous intraepithelial lesions (LSIL, 11.50%, 244/2,122; HPV52 [29.92%]), high-grade SIL (HSIL, 3.49%, 74/2,122; HPV16 [40.54%]), and cervical cancer (1.79%, 38/2,122; HPV16 [52.63%]). Notably, HPV16 prevalence increased significantly with lesion severity.

Conclusion: This study found that the overall HPV infection rate in Sanming, China, was slightly higher than in other regions of the country, and the main prevalent genotypes were HPV52 and HPV58. In order to maximize patient benefit, vaccine selection should ideally cover other common genotypes in the region, in addition to HPV16 and HPV18.

查看原文本刊更多论文

中国三明妇女HPV患病率和基因型分布：大规模疫苗接种前的回顾性分析

背景：在开展大规模HPV疫苗接种前研究三明市HPV流行情况，对指导公共卫生预防措施，实现疫苗接种效果最大化具有重要意义。目的：全面了解三明市HPV流行情况，指导今后开展HPV筛查和疫苗选择。方法：对11,886例接受宫颈筛查的女性患者进行回顾性分析。我们分析了该地区HPV的总体患病率、各年龄组和不同基因型的患病率以及不同病理诊断的HPV分布。结果：HPV总患病率为17.85%，其中≤20岁组阳性率最高（42.24%），61 ~ 70岁继发升高（31.90%）。HPV52（23.37%）、HPV58（14.00%）和HPV16（11.40%）为优势基因型。2122例hpv阳性患者中，病理诊断包括：慢性宫颈炎（83.22%,1766 / 2122）；主要是HPV52[22.88%])，低级别鳞状上皮内病变(LSIL, 11.50%, 244/ 2122；HPV52[29.92%])，高级别SIL (HSIL, 3.49%, 74/ 2122；HPV16[40.54%])和宫颈癌(1.79%,38/ 2122；HPV16[52.63%])。值得注意的是，HPV16患病率随病变严重程度显著增加。结论：本研究发现，中国三明地区HPV总体感染率略高于全国其他地区，主要流行基因型为HPV52和HPV58。为了使患者受益最大化，除了HPV16和HPV18之外，理想情况下疫苗选择应涵盖该地区其他常见基因型。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Infectious Agents and Cancer ONCOLOGY-IMMUNOLOGY

CiteScore

5.80

自引率

2.70%

发文量

期刊介绍： Infectious Agents and Cancer is an open access, peer-reviewed online journal that encompasses all aspects of basic, clinical, epidemiological and translational research providing an insight into the association between chronic infections and cancer. The journal welcomes submissions in the pathogen-related cancer areas and other related topics, in particular: • HPV and anogenital cancers, as well as head and neck cancers; • EBV and Burkitt lymphoma; • HCV/HBV and hepatocellular carcinoma as well as lymphoproliferative diseases; • HHV8 and Kaposi sarcoma; • HTLV and leukemia; • Cancers in Low- and Middle-income countries. The link between infection and cancer has become well established over the past 50 years, and infection-associated cancer contribute up to 16% of cancers in developed countries and 33% in less developed countries. Preventive vaccines have been developed for only two cancer-causing viruses, highlighting both the opportunity to prevent infection-associated cancers by vaccination and the gaps that remain before vaccines can be developed for other cancer-causing agents. These gaps are due to incomplete understanding of the basic biology, natural history, epidemiology of many of the pathogens that cause cancer, the mechanisms they exploit to cause cancer, and how to interrupt progression to cancer in human populations. Early diagnosis or identification of lesions at high risk of progression represent the current most critical research area of the field supported by recent advances in genomics and proteomics technologies.